25 XP   0   0   10

Lumos Pharma Inc
Buy, Hold or Sell?

Let's analyse Lumos Pharma Inc together

PenkeI guess you are interested in Lumos Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lumos Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lumos Pharma Inc

I send you an email if I find something interesting about Lumos Pharma Inc.

Quick analysis of Lumos Pharma Inc (30 sec.)










What can you expect buying and holding a share of Lumos Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
22.5%

What is your share worth?

Current worth
$3.37
Expected worth in 1 year
$-0.38
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
$-3.75
Return On Investment
-132.9%

For what price can you sell your share?

Current Price per Share
$2.82
Expected price per share
$2.5101 - $3.303
How sure are you?
50%

1. Valuation of Lumos Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$2.82

Intrinsic Value Per Share

$-29.56 - $-21.06

Total Value Per Share

$-26.19 - $-17.70

2. Growth of Lumos Pharma Inc (5 min.)




Is Lumos Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$27.3m$70.9m-$31.1m-78.4%

How much money is Lumos Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$8.3m-$7.5m-$812k-9.7%
Net Profit Margin-30,593.6%-2,942.2%--

How much money comes from the company's main activities?

3. Financial Health of Lumos Pharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#565 / 1031

Most Revenue
#543 / 1031

Most Profit
#557 / 1031

Most Efficient
#993 / 1031

What can you expect buying and holding a share of Lumos Pharma Inc? (5 min.)

Welcome investor! Lumos Pharma Inc's management wants to use your money to grow the business. In return you get a share of Lumos Pharma Inc.

What can you expect buying and holding a share of Lumos Pharma Inc?

First you should know what it really means to hold a share of Lumos Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Lumos Pharma Inc is $2.82. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lumos Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lumos Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.37. Based on the TTM, the Book Value Change Per Share is $-0.94 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.88 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lumos Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.17-41.4%-1.09-38.7%-0.93-32.9%-0.89-31.5%-0.90-31.9%
Usd Book Value Change Per Share-1.01-35.8%-0.94-33.2%-0.88-31.3%-0.54-19.2%-0.10-3.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.5%
Usd Total Gains Per Share-1.01-35.8%-0.94-33.2%-0.88-31.3%-0.54-19.2%-0.08-2.9%
Usd Price Per Share3.18-3.27-7.39-8.14-14.26-
Price to Earnings Ratio-0.68--0.75--2.02--4.95--3.40-
Price-to-Total Gains Ratio-3.15--3.56--8.51-4.31--3.58-
Price to Book Ratio0.94-0.71-0.86-0.77-0.98-
Price-to-Total Gains Ratio-3.15--3.56--8.51-4.31--3.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.82
Number of shares354
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.94-0.54
Usd Total Gains Per Share-0.94-0.54
Gains per Quarter (354 shares)-331.65-191.76
Gains per Year (354 shares)-1,326.61-767.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1327-13370-767-777
20-2653-26640-1534-1544
30-3980-39910-2301-2311
40-5306-53180-3068-3078
50-6633-66450-3835-3845
60-7960-79720-4603-4612
70-9286-92990-5370-5379
80-10613-106261-6137-6146
90-11939-119531-6904-6913
100-13266-132801-7671-7680

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.037.00.07.5%3.052.00.05.5%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%7.033.00.017.5%11.043.01.020.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%9.00.031.022.5%12.00.043.021.8%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%7.033.00.017.5%12.042.01.021.8%

Fundamentals of Lumos Pharma Inc

About Lumos Pharma Inc

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2024-03-20 23:09:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lumos Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lumos Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -1,144.9% means that $-11.45 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lumos Pharma Inc:

  • The MRQ is -1,144.9%. The company is making a huge loss. -2
  • The TTM is -30,593.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,144.9%TTM-30,593.6%+29,448.7%
TTM-30,593.6%YOY-2,942.2%-27,651.4%
TTM-30,593.6%5Y-25,422.7%-5,170.9%
5Y-25,422.7%10Y-14,579.7%-10,842.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,144.9%-159.2%-985.7%
TTM-30,593.6%-202.3%-30,391.3%
YOY-2,942.2%-263.0%-2,679.2%
5Y-25,422.7%-452.4%-24,970.3%
10Y-14,579.7%-589.0%-13,990.7%
1.1.2. Return on Assets

Shows how efficient Lumos Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • -23.3% Return on Assets means that Lumos Pharma Inc generated $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lumos Pharma Inc:

  • The MRQ is -23.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.3%TTM-16.7%-6.5%
TTM-16.7%YOY-9.2%-7.5%
TTM-16.7%5Y-8.6%-8.1%
5Y-8.6%10Y-7.4%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.3%-12.5%-10.8%
TTM-16.7%-12.2%-4.5%
YOY-9.2%-11.2%+2.0%
5Y-8.6%-13.3%+4.7%
10Y-7.4%-14.6%+7.2%
1.1.3. Return on Equity

Shows how efficient Lumos Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • -34.6% Return on Equity means Lumos Pharma Inc generated $-0.35 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lumos Pharma Inc:

  • The MRQ is -34.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-34.6%TTM-22.8%-11.8%
TTM-22.8%YOY-10.7%-12.0%
TTM-22.8%5Y-10.8%-11.9%
5Y-10.8%10Y-9.2%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-34.6%-16.0%-18.6%
TTM-22.8%-15.8%-7.0%
YOY-10.7%-13.9%+3.2%
5Y-10.8%-18.2%+7.4%
10Y-9.2%-19.1%+9.9%

1.2. Operating Efficiency of Lumos Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lumos Pharma Inc is operating .

  • Measures how much profit Lumos Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,211.1% means the company generated $-12.11  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lumos Pharma Inc:

  • The MRQ is -1,211.1%. The company is operating very inefficient. -2
  • The TTM is -32,979.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,211.1%TTM-32,979.9%+31,768.8%
TTM-32,979.9%YOY-3,044.0%-29,936.0%
TTM-32,979.9%5Y-29,059.7%-3,920.2%
5Y-29,059.7%10Y-16,598.5%-12,461.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,211.1%-299.5%-911.6%
TTM-32,979.9%-208.5%-32,771.4%
YOY-3,044.0%-280.2%-2,763.8%
5Y-29,059.7%-459.9%-28,599.8%
10Y-16,598.5%-596.9%-16,001.6%
1.2.2. Operating Ratio

Measures how efficient Lumos Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 13.11 means that the operating costs are $13.11 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lumos Pharma Inc:

  • The MRQ is 13.111. The company is inefficient in keeping operating costs low. -1
  • The TTM is 330.803. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ13.111TTM330.803-317.691
TTM330.803YOY31.457+299.346
TTM330.8035Y288.409+42.393
5Y288.40910Y158.014+130.395
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.1112.817+10.294
TTM330.8033.181+327.622
YOY31.4573.609+27.848
5Y288.4095.554+282.855
10Y158.0147.396+150.618

1.3. Liquidity of Lumos Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lumos Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.69 means the company has $5.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lumos Pharma Inc:

  • The MRQ is 5.695. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.654. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.695TTM8.654-2.959
TTM8.654YOY15.094-6.440
TTM8.6545Y12.966-4.312
5Y12.96610Y12.336+0.630
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6953.987+1.708
TTM8.6544.440+4.214
YOY15.0945.569+9.525
5Y12.9666.158+6.808
10Y12.3366.492+5.844
1.3.2. Quick Ratio

Measures if Lumos Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.30 means the company can pay off $5.30 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lumos Pharma Inc:

  • The MRQ is 5.304. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.411. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.304TTM9.411-4.108
TTM9.411YOY14.574-5.162
TTM9.4115Y12.596-3.185
5Y12.59610Y11.969+0.627
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3043.653+1.651
TTM9.4114.158+5.253
YOY14.5745.515+9.059
5Y12.5966.012+6.584
10Y11.9696.206+5.763

1.4. Solvency of Lumos Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lumos Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lumos Pharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Lumos Pharma Inc assets are financed with 32.8% credit (debt) and the remaining percentage (100% - 32.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lumos Pharma Inc:

  • The MRQ is 0.328. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.247. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.247+0.082
TTM0.247YOY0.143+0.104
TTM0.2475Y0.180+0.066
5Y0.18010Y0.170+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3280.336-0.008
TTM0.2470.330-0.083
YOY0.1430.267-0.124
5Y0.1800.367-0.187
10Y0.1700.378-0.208
1.4.2. Debt to Equity Ratio

Measures if Lumos Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 48.8% means that company has $0.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lumos Pharma Inc:

  • The MRQ is 0.488. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.335. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.488TTM0.335+0.154
TTM0.335YOY0.167+0.167
TTM0.3355Y0.232+0.103
5Y0.23210Y0.214+0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4880.376+0.112
TTM0.3350.398-0.063
YOY0.1670.334-0.167
5Y0.2320.431-0.199
10Y0.2140.476-0.262

2. Market Valuation of Lumos Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lumos Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Lumos Pharma Inc to the Biotechnology industry mean.
  • A PE ratio of -0.68 means the investor is paying $-0.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lumos Pharma Inc:

  • The EOD is -0.604. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.682. Based on the earnings, the company is expensive. -2
  • The TTM is -0.751. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.604MRQ-0.682+0.077
MRQ-0.682TTM-0.751+0.070
TTM-0.751YOY-2.018+1.267
TTM-0.7515Y-4.949+4.198
5Y-4.94910Y-3.404-1.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.604-2.697+2.093
MRQ-0.682-2.422+1.740
TTM-0.751-2.709+1.958
YOY-2.018-4.116+2.098
5Y-4.949-6.257+1.308
10Y-3.404-6.478+3.074
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lumos Pharma Inc:

  • The EOD is -0.773. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.872. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.684. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.773MRQ-0.872+0.099
MRQ-0.872TTM-1.684+0.812
TTM-1.684YOY-2.331+0.647
TTM-1.6845Y1.392-3.076
5Y1.39210Y-1.958+3.350
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.773-3.344+2.571
MRQ-0.872-2.939+2.067
TTM-1.684-3.486+1.802
YOY-2.331-5.592+3.261
5Y1.392-8.464+9.856
10Y-1.958-8.872+6.914
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lumos Pharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.94 means the investor is paying $0.94 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lumos Pharma Inc:

  • The EOD is 0.837. Based on the equity, the company is cheap. +2
  • The MRQ is 0.944. Based on the equity, the company is cheap. +2
  • The TTM is 0.709. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.837MRQ0.944-0.107
MRQ0.944TTM0.709+0.236
TTM0.709YOY0.857-0.148
TTM0.7095Y0.773-0.065
5Y0.77310Y0.981-0.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8372.198-1.361
MRQ0.9442.042-1.098
TTM0.7092.121-1.412
YOY0.8572.907-2.050
5Y0.7733.682-2.909
10Y0.9814.114-3.133
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lumos Pharma Inc.

3.1. Institutions holding Lumos Pharma Inc

Institutions are holding 29.381% of the shares of Lumos Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Blackstone Inc5.9150.006546814500
2023-09-30Wells Fargo & Co5.26310.00044165499466029.4077
2023-09-30Goldman Sachs Group Inc5.13680.0003406558-386-0.0949
2023-09-30Vanguard Group Inc2.97470235437-1531-0.6461
2023-12-31Renaissance Technologies Corp2.80010.0011221614-5100-2.2495
2023-09-30Acuitas Investments, LLC1.58240.243125242-28625-18.6037
2023-09-30Jefferies Financial Group Inc1.52440.003612065100
2023-12-31Lion Point Capital, LP1.14720.14459079400
2023-12-31Greenwich Wealth Management LLC0.96460.0247634100
2023-12-31Bridgeway Capital Management, LLC0.6020.00324764300
2023-09-30Geode Capital Management, LLC0.6014047596-6683-12.3123
2023-09-30BlackRock Inc0.5491043460-3320-7.0971
2023-12-31Two Sigma Investments LLC0.53850.000342619426190
2023-12-31Two Sigma Advisers, LLC0.35760.000228300283000
2023-09-30Marquette Asset Management Inc.0.32550.020225760-5328-17.1384
2023-09-30Private Advisor Group, LLC0.25290.000620013600042.8174
2023-12-31Dimensional Fund Advisors, Inc.0.196601556400
2023-09-30Bank of New York Mellon Corp0.149801185800
2023-12-31Wealth Advisors OF Iowa, LLC0.14780.0251169900
2023-09-30State Street Corporation0.14201123700
Total 31.17150.47292467080+120606+4.9%

3.2. Funds holding Lumos Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Total Stock Mkt Idx Inv2.3119018732200
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.62730.00025082800
2023-09-30Bridgeway Ultra-Small Company Market0.57690.09184674400
2024-01-31Fidelity Extended Market Index0.31930.00022587000
2024-01-31Fidelity Nasdaq Composite Index0.12390.00021003700
2023-09-30BlackRock Extended Mkt Composite0.0790.0002640400
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.07320.00015932-181390-96.8333
2024-01-31Vanguard Instl Ttl Stk Mkt Idx InstlPls0.07320.0001593200
2023-12-31BlackRock Extended Equity Market K0.0690.00015587-11-0.1965
2024-01-31Fidelity Series Total Market Index0.06620536700
2024-01-31Dimensional Global Trgtd Value USD Acc0.06560.0003531900
2024-02-29Dimensional US Core Equity 2 ETF0.04560369500
2023-12-31Northern Trust Extended Eq Market Idx0.04460.0002361400
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04460.0002361400
2024-01-31Fidelity Total Market Index0.04010325100
2024-02-29Dimensional US Equity ETF0.03930.0001318700
2023-12-31SSgA U.S. Extended Market Index Class I0.03410.0003276500
2024-02-29State St US Extended Mkt Indx NL Cl C0.03410.0004276500
2024-01-31DFA US Core Equity 2 I0.03220260600
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03210.0001260100
Total 4.73220.0945383440-181401-47.3%

3.3. Insider Transactions

Insiders are holding 34.538% of the shares of Lumos Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-06John C MckewSELL4383.03
2023-08-02John C MckewSELL34073.21
2023-04-04John C MckewSELL22143.27

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Lumos Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.010-0.937-7%-0.883-13%-0.542-46%-0.096-91%
Book Value Per Share--3.3684.867-31%8.472-60%10.138-67%13.881-76%
Current Ratio--5.6958.654-34%15.094-62%12.966-56%12.336-54%
Debt To Asset Ratio--0.3280.247+33%0.143+130%0.180+82%0.170+93%
Debt To Equity Ratio--0.4880.335+46%0.167+192%0.232+111%0.214+128%
Dividend Per Share----0%-0%0.000-100%0.014-100%
Eps---1.167-1.092-6%-0.928-20%-0.887-24%-0.901-23%
Free Cash Flow Per Share---0.912-0.951+4%-0.796-13%-0.851-7%-0.657-28%
Free Cash Flow To Equity Per Share---0.820-0.968+18%-0.8200%-0.861+5%-0.249-70%
Gross Profit Margin--1.0021.000+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---21.064--------
Intrinsic Value_10Y_min---29.560--------
Intrinsic Value_1Y_max---2.557--------
Intrinsic Value_1Y_min---3.433--------
Intrinsic Value_3Y_max---7.343--------
Intrinsic Value_3Y_min---9.969--------
Intrinsic Value_5Y_max---11.719--------
Intrinsic Value_5Y_min---16.074--------
Market Cap22862078.400-13%25780641.60026687883.053-3%61862521.390-58%67817781.790-62%116550845.395-78%
Net Profit Margin---11.449-305.936+2572%-29.422+157%-254.227+2120%-145.797+1173%
Operating Margin---12.111-329.799+2623%-30.440+151%-290.597+2299%-165.985+1270%
Operating Ratio--13.111330.803-96%31.457-58%288.409-95%158.014-92%
Pb Ratio0.837-13%0.9440.709+33%0.857+10%0.773+22%0.981-4%
Pe Ratio-0.604+11%-0.682-0.751+10%-2.018+196%-4.949+626%-3.404+399%
Price Per Share2.820-13%3.1803.273-3%7.390-57%8.142-61%14.265-78%
Price To Free Cash Flow Ratio-0.773+11%-0.872-1.684+93%-2.331+167%1.392-163%-1.958+125%
Price To Total Gains Ratio-2.792+11%-3.149-3.558+13%-8.514+170%4.314-173%-3.581+14%
Quick Ratio--5.3049.411-44%14.574-64%12.596-58%11.969-56%
Return On Assets---0.233-0.167-28%-0.092-61%-0.086-63%-0.074-68%
Return On Equity---0.346-0.228-34%-0.107-69%-0.108-69%-0.092-73%
Total Gains Per Share---1.010-0.937-7%-0.883-13%-0.542-46%-0.082-92%
Usd Book Value--27305000.00039744250.000-31%70913500.000-61%83995850.000-67%113434975.000-76%
Usd Book Value Change Per Share---1.010-0.937-7%-0.883-13%-0.542-46%-0.096-91%
Usd Book Value Per Share--3.3684.867-31%8.472-60%10.138-67%13.881-76%
Usd Dividend Per Share----0%-0%0.000-100%0.014-100%
Usd Eps---1.167-1.092-6%-0.928-20%-0.887-24%-0.901-23%
Usd Free Cash Flow---7393000.000-7773750.000+5%-6661000.000-10%-7031350.000-5%-5393500.000-27%
Usd Free Cash Flow Per Share---0.912-0.951+4%-0.796-13%-0.851-7%-0.657-28%
Usd Free Cash Flow To Equity Per Share---0.820-0.968+18%-0.8200%-0.861+5%-0.249-70%
Usd Market Cap22862078.400-13%25780641.60026687883.053-3%61862521.390-58%67817781.790-62%116550845.395-78%
Usd Price Per Share2.820-13%3.1803.273-3%7.390-57%8.142-61%14.265-78%
Usd Profit---9457000.000-8336250.000-12%-7524250.000-20%-7126200.000-25%-7268725.000-23%
Usd Revenue--826000.000512750.000+61%380750.000+117%247569.250+234%6455259.625-87%
Usd Total Gains Per Share---1.010-0.937-7%-0.883-13%-0.542-46%-0.082-92%
 EOD+3 -5MRQTTM+12 -22YOY+7 -275Y+9 -2710Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Lumos Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.604
Price to Book Ratio (EOD)Between0-10.837
Net Profit Margin (MRQ)Greater than0-11.449
Operating Margin (MRQ)Greater than0-12.111
Quick Ratio (MRQ)Greater than15.304
Current Ratio (MRQ)Greater than15.695
Debt to Asset Ratio (MRQ)Less than10.328
Debt to Equity Ratio (MRQ)Less than10.488
Return on Equity (MRQ)Greater than0.15-0.346
Return on Assets (MRQ)Greater than0.05-0.233
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Lumos Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.604
Ma 20Greater thanMa 502.902
Ma 50Greater thanMa 1002.948
Ma 100Greater thanMa 2003.021
OpenGreater thanClose2.810
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets40,638
Total Liabilities13,333
Total Stockholder Equity27,305
 As reported
Total Liabilities 13,333
Total Stockholder Equity+ 27,305
Total Assets = 40,638

Assets

Total Assets40,638
Total Current Assets40,035
Long-term Assets603
Total Current Assets
Cash And Cash Equivalents 35,078
Short-term Investments 999
Net Receivables 210
Other Current Assets 3,748
Total Current Assets  (as reported)40,035
Total Current Assets  (calculated)40,035
+/-0
Long-term Assets
Property Plant Equipment 603
Long-term Assets  (as reported)603
Long-term Assets  (calculated)603
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,030
Long-term Liabilities6,303
Total Stockholder Equity27,305
Total Current Liabilities
Short-term Debt 282
Accounts payable 890
Other Current Liabilities 5,858
Total Current Liabilities  (as reported)7,030
Total Current Liabilities  (calculated)7,030
+/-0
Long-term Liabilities
Capital Lease Obligations 585
Long-term Liabilities  (as reported)6,303
Long-term Liabilities  (calculated)585
+/- 5,718
Total Stockholder Equity
Common Stock81
Retained Earnings -161,517
Other Stockholders Equity 188,741
Total Stockholder Equity (as reported)27,305
Total Stockholder Equity (calculated)27,305
+/-0
Other
Capital Stock81
Cash and Short Term Investments 36,077
Common Stock Shares Outstanding 8,102
Liabilities and Stockholders Equity 40,638
Net Debt -28,493
Net Invested Capital 27,305
Net Working Capital 33,005
Property Plant and Equipment Gross 603
Short Long Term Debt Total 6,585



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302009-12-31
> Total Assets 
22,667
14,450
20,078
0
17,315
13,974
48,379
43,447
39,136
35,008
29,429
71,655
67,013
60,887
70,557
91,743
84,670
85,877
238,062
259,127
243,250
226,819
218,542
199,923
179,449
186,344
174,747
149,622
136,124
139,714
180,697
165,037
148,013
139,315
130,939
129,271
120,811
106,654
96,787
182,955
172,198
136,188
129,033
120,062
114,269
106,465
100,312
93,190
85,453
79,209
72,292
63,725
56,373
47,751
40,638
40,63847,75156,37363,72572,29279,20985,45393,190100,312106,465114,269120,062129,033136,188172,198182,95596,787106,654120,811129,271130,939139,315148,013165,037180,697139,714136,124149,622174,747186,344179,449199,923218,542226,819243,250259,127238,06285,87784,67091,74370,55760,88767,01371,65529,42935,00839,13643,44748,37913,97417,315020,07814,45022,667
   > Total Current Assets 
18,898
8,817
14,642
0
12,098
8,882
42,788
37,218
32,871
28,921
23,389
65,766
61,071
54,149
63,970
85,309
78,214
78,760
230,463
251,099
234,452
217,191
208,142
189,425
172,014
179,156
167,912
143,156
130,238
134,187
175,466
160,199
143,486
135,079
127,072
118,277
110,198
102,654
94,419
93,159
170,737
135,155
128,449
119,601
113,476
105,754
99,677
92,645
84,988
78,832
72,009
63,253
55,983
47,447
40,035
40,03547,44755,98363,25372,00978,83284,98892,64599,677105,754113,476119,601128,449135,155170,73793,15994,419102,654110,198118,277127,072135,079143,486160,199175,466134,187130,238143,156167,912179,156172,014189,425208,142217,191234,452251,099230,46378,76078,21485,30963,97054,14961,07165,76623,38928,92132,87137,21842,7888,88212,098014,6428,81718,898
       Cash And Cash Equivalents 
15,217
5,809
10,572
0
9,550
6,287
39,490
33,269
30,327
25,557
20,250
63,278
59,039
51,964
61,291
83,713
76,861
51,070
190,404
206,593
203,377
197,141
195,620
176,986
160,527
148,276
131,490
118,240
107,777
120,702
158,708
143,891
137,066
122,061
120,738
113,184
105,372
98,527
90,549
85,821
72,697
105,575
98,679
114,101
107,696
100,650
94,809
86,758
79,511
73,666
56,007
44,038
37,862
35,557
35,078
35,07835,55737,86244,03856,00773,66679,51186,75894,809100,650107,696114,10198,679105,57572,69785,82190,54998,527105,372113,184120,738122,061137,066143,891158,708120,702107,777118,240131,490148,276160,527176,986195,620197,141203,377206,593190,40451,07076,86183,71361,29151,96459,03963,27820,25025,55730,32733,26939,4906,2879,550010,5725,80915,217
       Short-term Investments 
0
0
2,269
0
250
0
2,490
2,490
747
2,739
1,494
747
249
0
249
249
249
16,636
12,393
7,776
4,202
3,216
2,180
997
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,352
13,945
12,989
7,137
999
9997,13712,98913,94511,352000000000000000000000000009972,1803,2164,2027,77612,39316,63624924924902497471,4942,7397472,4902,490025002,26900
       Net Receivables 
1,579
576
842
0
699
598
399
1,167
1,543
480
738
1,084
1,248
1,780
1,657
668
658
7,502
15,604
14,190
2,519
76
5,388
8,610
4,259
5,197
5,975
15,932
17,545
10,784
10,532
10,692
1,177
8,098
798
646
811
816
824
5,020
4,962
26,350
26,264
194
125
116
128
134
149
168
223
200
233
172
210
21017223320022316814913412811612519426,26426,3504,9625,0208248168116467988,0981,17710,69210,53210,78417,54515,9325,9755,1974,2598,6105,388762,51914,19015,6047,5026586681,6571,7801,2481,0847384801,5431,16739959869908425761,579
       Inventory 
110
440
0
0
0
-6,885
409
292
254
145
-738
-1,084
-1,248
0
0
-668
-658
0
3,729
11,316
13,010
14,990
-5,388
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,920
0
0
0
0
0
-128
0
0
0
0
0
0
0
0
00000000-1280000087,92000000000000000000-5,38814,99013,01011,3163,7290-658-66800-1,248-1,084-738145254292409-6,885000440110
       Other Current Assets 
1,992
1,992
959
0
1,599
8,882
2,490
2,490
747
2,739
1,645
1,741
2,032
405
773
1,347
1,104
3,552
8,333
11,224
11,344
1,768
10,342
2,832
7,228
25,683
30,447
8,984
4,916
2,701
6,226
5,616
5,243
4,920
5,536
4,447
4,015
3,311
3,046
2,318
5,158
3,230
3,506
5,306
5,655
4,988
4,740
5,753
5,328
4,998
4,427
5,070
4,899
4,581
3,748
3,7484,5814,8995,0704,4274,9985,3285,7534,7404,9885,6555,3063,5063,2305,1582,3183,0463,3114,0154,4475,5364,9205,2435,6166,2262,7014,9168,98430,44725,6837,2282,83210,3421,76811,34411,2248,3333,5521,1041,3477734052,0321,7411,6452,7397472,4902,4908,8821,59909591,9921,992
   > Long-term Assets 
3,769
5,633
5,436
0
5,217
5,092
5,591
6,229
6,265
6,087
6,040
5,889
5,942
6,738
6,587
6,434
6,456
7,117
7,599
8,028
8,798
9,628
10,400
10,498
7,435
7,188
6,835
6,466
5,886
5,527
5,231
4,838
4,527
4,236
3,867
10,994
10,613
4,000
2,368
89,796
1,461
1,033
584
461
793
711
635
545
465
377
283
472
390
304
603
6033043904722833774655456357117934615841,0331,46189,7962,3684,00010,61310,9943,8674,2364,5274,8385,2315,5275,8866,4666,8357,1887,43510,49810,4009,6288,7988,0287,5997,1176,4566,4346,5876,7385,9425,8896,0406,0876,2656,2295,5915,0925,21705,4365,6333,769
       Property Plant Equipment 
2,919
5,633
5,436
0
5,217
5,092
5,591
6,229
6,265
6,087
6,040
5,889
5,942
6,738
6,587
6,434
6,456
7,117
7,599
8,028
8,798
9,628
10,400
10,498
7,435
7,188
6,835
6,466
5,886
5,527
5,091
4,698
4,387
4,096
3,727
10,854
10,473
3,931
2,368
1,876
1,461
1,033
584
461
793
711
635
545
465
377
283
472
390
304
603
6033043904722833774655456357117934615841,0331,4611,8762,3683,93110,47310,8543,7274,0964,3874,6985,0915,5275,8866,4666,8357,1887,43510,49810,4009,6288,7988,0287,5997,1176,4566,4346,5876,7385,9425,8896,0406,0876,2656,2295,5915,0925,21705,4365,6332,919
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140
140
140
140
140
140
140
69
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000069140140140140140140140000000000000000000000000000000
       Long-term Assets Other 
850
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-7,502
-15,604
-14,190
-2,519
-76
0
-1,796
-4,259
-5,197
-5,975
-6,287
-6,287
-114
-216
-199
-220
-7,258
-199
140
140
69
735
79,410
-7,084
0
249
361
714
0
0
0
0
-377
-283
-472
-390
-304
0
0-304-390-472-283-37700007143612490-7,08479,41073569140140-199-7,258-220-199-216-114-6,287-6,287-5,975-5,197-4,259-1,7960-76-2,519-14,190-15,604-7,5020000000000000000850
> Total Liabilities 
63,453
64,325
72,097
0
9,888
85,356
11,606
10,649
10,904
11,785
11,502
11,661
12,655
13,537
12,230
11,918
12,073
15,486
34,285
26,296
17,491
19,407
22,768
23,110
30,105
48,067
45,281
35,268
33,521
33,250
29,140
27,083
23,067
17,120
15,796
22,252
22,124
20,257
17,909
61,417
55,733
17,653
12,461
11,090
13,147
12,341
11,335
11,373
10,907
11,502
12,708
11,206
12,712
12,259
13,333
13,33312,25912,71211,20612,70811,50210,90711,37311,33512,34113,14711,09012,46117,65355,73361,41717,90920,25722,12422,25215,79617,12023,06727,08329,14033,25033,52135,26845,28148,06730,10523,11022,76819,40717,49126,29634,28515,48612,07311,91812,23013,53712,65511,66111,50211,78510,90410,64911,60685,3569,888072,09764,32563,453
   > Total Current Liabilities 
3,241
9,053
3,265
0
8,843
9,094
10,664
2,310
2,616
3,150
2,919
3,141
4,163
5,114
3,876
3,632
3,857
7,238
25,102
17,562
9,036
11,215
14,840
15,305
22,545
40,645
37,905
27,971
26,303
26,091
22,031
20,018
16,041
10,132
8,847
8,872
8,628
14,040
11,827
46,767
42,561
6,965
6,461
4,984
6,777
6,053
5,130
5,242
4,832
5,483
6,708
5,017
6,545
6,116
7,030
7,0306,1166,5455,0176,7085,4834,8325,2425,1306,0536,7774,9846,4616,96542,56146,76711,82714,0408,6288,8728,84710,13216,04120,01822,03126,09126,30327,97137,90540,64522,54515,30514,84011,2159,03617,56225,1027,2383,8573,6323,8765,1144,1633,1412,9193,1502,6162,31010,6649,0948,84303,2659,0533,241
       Short-term Debt 
35
6,208
207
0
6,215
6,223
6,214
216
204
230
204
177
186
188
189
190
190
193
192
591
587
580
571
248
242
245
232
234
222
194
160
112
93
74
61
1,026
704
1,770
1,143
953
742
535
319
261
348
349
352
345
320
294
233
232
179
126
282
2821261792322332943203453523493482613195357429531,1431,7707041,0266174931121601942222342322452422485715805875911921931901901891881861772042302042166,2146,2236,21502076,20835
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
63
58
43
27
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000011274358636300000000000000000000000000000000000
       Accounts payable 
1,080
379
552
0
313
256
1,670
803
575
708
972
865
1,076
973
3,473
972
687
2,935
2,412
4,113
1,474
1,494
12,422
3,039
1,843
2,367
22,883
9,618
11,369
11,860
9,256
5,316
7,334
1,238
555
896
689
145
475
2,362
155
137
244
357
312
149
612
1,799
854
710
275
837
279
488
890
8904882798372757108541,7996121493123572441371552,3624751456898965551,2387,3345,3169,25611,86011,3699,61822,8832,3671,8433,03912,4221,4941,4744,1132,4122,9356879723,4739731,0768659727085758031,67025631305523791,080
       Other Current Liabilities 
1,179
1,519
1,555
0
1,383
1,693
2,780
1,226
1,766
2,136
204
2,015
2,817
3,869
130
2,386
2,896
277
9,532
9,380
6,039
8,240
955
11,154
19,622
37,340
14,399
17,896
14,545
13,925
12,559
14,590
8,614
8,820
8,231
963
7,235
12,125
-256
35,720
35,720
6,293
5,898
4,366
6,117
5,555
4,166
3,098
3,658
4,479
6,200
3,948
6,087
5,502
5,858
5,8585,5026,0873,9486,2004,4793,6583,0984,1665,5556,1174,3665,8986,29335,72035,720-25612,1257,2359638,2318,8208,61414,59012,55913,92514,54517,89614,39937,34019,62211,1549558,2406,0399,3809,5322772,8962,3861303,8692,8172,0152042,1361,7661,2262,7801,6931,38301,5551,5191,179
   > Long-term Liabilities 
60,212
55,272
68,832
0
1,045
76,262
942
8,339
8,288
8,635
8,583
8,520
8,492
8,423
8,354
8,286
8,216
8,248
9,183
8,734
8,455
8,192
7,928
7,805
7,560
7,422
7,376
7,297
7,218
7,159
7,109
7,065
7,026
6,988
6,949
13,380
13,496
6,217
6,082
14,650
13,172
10,688
6,000
6,106
6,370
6,288
6,205
6,131
6,075
6,019
6,000
6,189
6,167
6,143
6,303
6,3036,1436,1676,1896,0006,0196,0756,1316,2056,2886,3706,1066,00010,68813,17214,6506,0826,21713,49613,3806,9496,9887,0267,0657,1097,1597,2187,2977,3767,4227,5607,8057,9288,1928,4558,7349,1838,2488,2168,2868,3548,4238,4928,5208,5838,6358,2888,33994276,2621,045068,83255,27260,212
       Long term Debt Total 
0
0
0
0
0
988
942
885
854
1,221
1,178
1,136
1,129
1,081
1,033
986
937
989
0
494
450
409
368
453
395
333
285
229
173
138
111
90
74
59
43
27
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000011274359749011113817322928533339545336840945049409899379861,0331,0811,1291,1361,1781,22185488594298800000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,510
13,084
10,653
6,000
6,000
6,000
6,000
6,000
6,000
6,000
6,000
6,000
0
6,000
0
0
006,00006,0006,0006,0006,0006,0006,0006,0006,0006,00010,65313,08414,510000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
1,454
1,434
1,414
1,405
1,384
1,363
1,342
1,321
1,300
1,279
1,259
0
2,240
2,005
1,783
1,560
1,352
1,165
1,089
1,091
1,068
7,045
7,021
6,998
6,975
6,952
6,929
6,906
6,000
6,000
6,000
6,000
14,510
13,084
0
6,000
6,000
6,000
0
0
0
0
0
0
0
0
0
0
00000000006,0006,0006,000013,08414,5106,0006,0006,0006,0006,9066,9296,9526,9756,9987,0217,0451,0681,0911,0891,1651,3521,5601,7832,0052,24001,2591,2791,3001,3211,3421,3631,3841,4051,4141,4341,4540000000
> Total Stockholder Equity
-43,138
-53,019
-54,962
0
7,427
-71,382
36,773
32,798
28,232
23,223
17,927
59,994
54,358
47,350
58,327
79,825
72,597
70,391
203,777
232,831
225,759
207,412
195,774
176,813
149,344
138,277
129,466
114,354
102,603
106,464
151,557
137,954
124,946
122,195
115,143
107,019
98,687
86,397
78,878
121,538
116,465
118,535
116,572
108,972
101,122
94,124
88,977
81,817
74,546
67,707
59,584
52,519
43,661
35,492
27,305
27,30535,49243,66152,51959,58467,70774,54681,81788,97794,124101,122108,972116,572118,535116,465121,53878,87886,39798,687107,019115,143122,195124,946137,954151,557106,464102,603114,354129,466138,277149,344176,813195,774207,412225,759232,831203,77770,39172,59779,82558,32747,35054,35859,99417,92723,22328,23232,79836,773-71,3827,4270-54,962-53,019-43,138
   Common Stock
67
73
36
0
144
37
206
207
208
209
210
256
257
257
266
279
279
279
280
285
287
288
288
289
290
291
292
292
292
314
372
373
373
373
373
373
373
373
374
83
83
83
83
83
83
83
83
83
83
83
82
81
80
79
81
81798081828383838383838383838383374373373373373373373373372314292292292291290289288288287285280279279279266257257256210209208207206371440367367
   Retained Earnings -161,517-152,060-143,760-134,829-127,483-119,236-111,985-104,141-96,421-90,780-83,292-74,622-65,991-63,576-65,341-59,988-334,001-325,730-311,182-301,048-291,012-280,443-273,040-255,727-237,459-223,773-203,147-186,421-165,508-152,002-136,462-104,073-80,353-58,779-36,032-21,929-33,119-159,974-154,376-145,213-135,977-127,931-119,808-112,731-104,797-98,478-92,627-86,318-81,476-75,666-71,6800-63,389-58,143-46,962
   Capital Surplus 
0
0
0
0
0
3,217
118,043
118,909
120,651
121,492
122,514
172,469
173,909
175,024
194,038
224,941
226,876
230,308
0
254,966
262,055
266,454
276,610
281,368
286,300
290,772
295,535
301,573
306,555
331,036
389,786
394,711
399,018
403,674
407,199
409,143
410,946
413,205
413,959
181,443
181,723
0
182,480
183,555
184,445
0
0
0
0
0
0
0
0
0
0
0000000000184,445183,555182,4800181,723181,443413,959413,205410,946409,143407,199403,674399,018394,711389,786331,036306,555301,573295,535290,772286,300281,368276,610266,454262,055254,9660230,308226,876224,941194,038175,024173,909172,469122,514121,492120,651118,909118,0433,21700000
   Treasury Stock0000000000-114-440000-1,454-1,451-1,450-1,449-1,417-1,409-1,405-1,403-1,142-1,113-1,098-1,090-853-784-784-771-771-551-551-4910-222-182-182000000000000000
   Other Stockholders Equity 
4,296
6,011
9,585
0
81,535
-1,067
118,043
118,909
120,651
121,492
122,514
172,469
173,909
175,024
194,038
224,759
226,694
230,086
236,616
254,475
261,504
265,903
275,839
280,597
285,516
289,988
294,682
300,483
305,458
329,923
388,644
393,308
397,613
402,265
405,782
407,694
409,496
411,754
412,505
181,443
181,723
182,028
182,480
183,511
184,331
184,821
185,315
185,875
186,448
186,860
186,994
187,272
187,352
187,477
188,741
188,741187,477187,352187,272186,994186,860186,448185,875185,315184,821184,331183,511182,480182,028181,723181,443412,505411,754409,496407,694405,782402,265397,613393,308388,644329,923305,458300,483294,682289,988285,516280,597275,839265,903261,504254,475236,616230,086226,694224,759194,038175,024173,909172,469122,514121,492120,651118,909118,043-1,06781,53509,5856,0114,296



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,051
Cost of Revenue-44
Gross Profit2,0072,007
 
Operating Income (+$)
Gross Profit2,007
Operating Expense-38,621
Operating Income-36,614-36,614
 
Operating Expense (+$)
Research Development22,096
Selling General Administrative16,569
Selling And Marketing Expenses44
Operating Expense38,62138,709
 
Net Interest Income (+$)
Interest Income2,078
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,078
 
Pretax Income (+$)
Operating Income-36,614
Net Interest Income2,078
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-34,063-39,165
EBIT - interestExpense = -36,614
-34,063
-34,034
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-36,614-34,063
Earnings Before Interest and Taxes (EBITDA)-36,570
 
After tax Income (+$)
Income Before Tax-34,063
Tax Provision--42
Net Income From Continuing Ops-32,824-34,021
Net Income-34,034
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses38,665
Total Other Income/Expenses Net2,551-2,078
 

Technical Analysis of Lumos Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lumos Pharma Inc. The general trend of Lumos Pharma Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lumos Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lumos Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.1245 < 3.25 < 3.303.

The bearish price targets are: 2.5101.

Tweet this
Lumos Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lumos Pharma Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lumos Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lumos Pharma Inc. The current macd is -0.04988685.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lumos Pharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lumos Pharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lumos Pharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lumos Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartLumos Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lumos Pharma Inc. The current adx is 23.61.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lumos Pharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Lumos Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lumos Pharma Inc. The current sar is 3.1711786.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lumos Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lumos Pharma Inc. The current rsi is 45.60. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Lumos Pharma Inc Daily Relative Strength Index (RSI) ChartLumos Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lumos Pharma Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lumos Pharma Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Lumos Pharma Inc Daily Stochastic Oscillator ChartLumos Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lumos Pharma Inc. The current cci is -23.92960865.

Lumos Pharma Inc Daily Commodity Channel Index (CCI) ChartLumos Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lumos Pharma Inc. The current cmo is -8.20708676.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lumos Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartLumos Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lumos Pharma Inc. The current willr is -47.46567215.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lumos Pharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lumos Pharma Inc Daily Williams %R ChartLumos Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lumos Pharma Inc.

Lumos Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lumos Pharma Inc. The current atr is 0.15868138.

Lumos Pharma Inc Daily Average True Range (ATR) ChartLumos Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lumos Pharma Inc. The current obv is 5,485,200.

Lumos Pharma Inc Daily On-Balance Volume (OBV) ChartLumos Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lumos Pharma Inc. The current mfi is 63.16.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Lumos Pharma Inc Daily Money Flow Index (MFI) ChartLumos Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lumos Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Lumos Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lumos Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.604
Ma 20Greater thanMa 502.902
Ma 50Greater thanMa 1002.948
Ma 100Greater thanMa 2003.021
OpenGreater thanClose2.810
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lumos Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Lumos Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lumos Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lumos Pharma Inc

I send you an email if I find something interesting about Lumos Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lumos Pharma Inc.

Receive notifications about Lumos Pharma Inc in your mailbox!